April 13, 2025 a 08:00 am
INCY: Fundamental Ratio Analysis - Incyte Corporation
Incyte Corporation, a key player in the biopharmaceutical industry, presents a moderate investment opportunity with some promising therapeutics in its pipeline. Given its solid position in performing treatments for complex diseases, INCY's stock is an interesting prospect, albeit with potential market challenges. Investors should consider both opportunities and risks inferred from its current ratings and market performance.
Fundamental Rating
The fundamental rating of Incyte Corporation reflects a balanced performance in key financial areas. The overall score signals a moderate rating standing.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 3 | |
| Return on Assets | 4 | |
| Debt to Equity | 3 | |
| Price to Earnings | 1 | |
| Price to Book | 2 |
Historical Rating
Historical data suggests a consistent performance with mild score variations over time.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-04-11 | 3 | 4 | 3 | 4 | 3 | 1 | 2 |
| Previous | 0 | 4 | 3 | 4 | 3 | 1 | 2 |
Analyst Price Targets
The analyst price targets highlight a broad range between the high and low, with a consensus adjusted to a more moderate outlook.
| High | Low | Median | Consensus |
|---|---|---|---|
| 200 | 82 | 91 | 107.5 |
Analyst Sentiment
Analysts maintain a generally positive sentiment, with a higher tendency towards 'Buy'.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 19 | |
| Hold | 17 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Incyte Corporation stands as a reliable entity in the biopharmaceutical sector, with strong collaborative agreements enhancing its innovative edge. The firm's current pipeline brings both opportunities and risks, hinging on successful regulatory progress and market performance of its therapies. While financial ratios demonstrate moderate health, price volatility may pose challenges. Analysts largely project positive sentiment, tilting towards buy recommendations. Overall, potential investors should balance this optimism with due diligence reflecting both the stock's prospects and inherent uncertainties in the biotech market.